Table 3.
Characteristic | PFS | LRFS | RRFS | DMFS |
---|---|---|---|---|
Sex | 0.15 | 0.059 | 0.56 | 0.42 |
Age (≤50 y vs >50 y) | 0.37 | 0.70 | 0.38 | 0.12 |
Time to disease recurrence (≤2 y vs >2 y) | 0.23 | 0.37 | 0.30 | 0.18 |
T classification (T1/2 vs T3/4) | 0.38 | 0.59 | 0.50 | 0.49 |
N classification (N+ vs N‐) | 0.14 | 0.12 | 0.56 | 0.42 |
Chemotherapyb | 0.13 | 0.43 | 0.50 | 0.51 |
GTV dose (<60 GyE vs ≥60 GyE) | 0.19 | 0.30 | 0.61 | 0.37 |
Fractionation (<3 GyE vs 3 GyE) | 0.027 | 0.058 | 0.48 | 0.24 |
BED (<74.1 GyE vs ≥74.1 GyE)c | 0.035 | 0.10 | 0.50 | 0.26 |
Abbreviations: BED, biological equivalent dose; DMFS, distant metastasis‐free survival, GTV, gross (macroscopic) tumor volume; GyE, Gray equivalent; LRFS, local recurrence‐free survival; PFS, progression‐free survival; RRFS, regional recurrence‐free survival.
Bold type indicates statistical significance.
Induction and/or concurrent chemotherapy.
The median BED was 74.1 GyE.